HALOZYME THERAPEUTICS, INC. (HALO)

HALOZYME THERAPEUTICS, INC. (HALO) scores 74 out of 100 on boothcheck's 11-model valuation framework. Verdict: Good The estimated fair value is 224.85, representing a 249% margin of safety. Quantitative score: 75/100. Qualitative score: 70/100.

Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.

View full HALO analysis on boothcheck